Xavier Roblin

32PUBLICATIONS
55CO-AUTHORS
Other European languagesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Rheumatology and arthritisEpidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Sep 28, 2026
Persistence, Safety and Pharmacokinetics of Vedolizumab After Switching to the Subcutaneous Route in a Prospective French National Cohort Study.

|Mar 24, 2026
Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis.

Emmanuel Niyigena, Yannick Hoffert, Waqqas Afif

|Dec 02, 2024
One Concentration Does Not Fit All: It Is Time to Personalize the Therapeutic Range of Infliximab in Crohn Disease.

Bénédicte Franck, Camille Tron, Marie-Clémence Verdier

|Feb 28, 2023
Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study.

Mathurin Fumery, Stéphane Nancey, Jérôme Filippi

|Dec 19, 2022
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.

Mathurin Fumery, Antoine Defrance, Xavier Roblin

|Apr 27, 2022
Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study.

Niels Vande Casteele, William J Sandborn, Brian G Feagan

Pageof 6

Frequent Collaborators

13 joint publications

Stephane Paul

11 joint publications

Laurent Peyrin-Biroulet

8 joint publications

David Laharie

7 joint publications

Aurelien Amiot